This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a potent media... See more...

Aliases for CYP4F2 Gene

Aliases for CYP4F2 Gene

  • Cytochrome P450 Family 4 Subfamily F Member 2 2 3 5
  • Cytochrome P450, Family 4, Subfamily F, Polypeptide 2 2 3
  • Cytochrome P450, Subfamily IVF, Polypeptide 2 2 3
  • 20-Hydroxyeicosatetraenoic Acid Synthase 3 4
  • Docosahexaenoic Acid Omega-Hydroxylase 3 4
  • Phylloquinone Omega-Hydroxylase CYP4F2 3 4
  • Leukotriene-B(4) Omega-Hydroxylase 1 3 4
  • Leukotriene-B(4) 20-Monooxygenase 1 3 4
  • Arachidonic Acid Omega-Hydroxylase 3 4
  • Cytochrome P450-LTB-Omega 3 4
  • Cytochrome P450 4F2 3 4
  • 20-HETE Synthase 3 4
  • CYPIVF2 3 4
  • EC 1.14.14.79 4
  • EC 1.14.14.94 4
  • EC 1.14.14.78 4
  • EC 1.14.14.1 4
  • CYP4F2 5
  • CPF2 3

External Ids for CYP4F2 Gene

Previous GeneCards Identifiers for CYP4F2 Gene

  • GC19M016474
  • GC19M015725
  • GC19M015849
  • GC19M015988
  • GC19M015560

Summaries for CYP4F2 Gene

Entrez Gene Summary for CYP4F2 Gene

  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a potent mediator of inflammation. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F11, is approximately 16 kb away. [provided by RefSeq, Jul 2008]

GeneCards Summary for CYP4F2 Gene

CYP4F2 (Cytochrome P450 Family 4 Subfamily F Member 2) is a Protein Coding gene. Diseases associated with CYP4F2 include Coumarin Resistance and Atrial Fibrillation. Among its related pathways are Arachidonic acid metabolism and Cytochrome P450 - arranged by substrate type. Gene Ontology (GO) annotations related to this gene include iron ion binding and oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen. An important paralog of this gene is CYP4F3.

UniProtKB/Swiss-Prot Summary for CYP4F2 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins (PubMed:18577768, PubMed:10833273, PubMed:10660572, PubMed:11997390, PubMed:17341693, PubMed:18574070). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs) (PubMed:18577768). Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:10660572, PubMed:17341693, PubMed:18574070). Plays a role in the oxidative inactivation of eicosanoids, including both proinflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs (PubMed:8026587, PubMed:9799565, PubMed:10833273, PubMed:10660572, PubMed:17341693, PubMed:18574070, PubMed:18577768). Catalyzes omega-hydroxylation of 3-hydroxy fatty acids (PubMed:18065749). Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites (PubMed:15145985). Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening (PubMed:16547005, PubMed:18182499). Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues (PubMed:11997390). Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation (PubMed:19297519, PubMed:24138531).

Gene Wiki entry for CYP4F2 Gene

PharmGKB "VIP" Summary for CYP4F2 Gene

No data available for CIViC Summary , Tocris Summary , Rfam classification and piRNA Summary for CYP4F2 Gene

Genomics for CYP4F2 Gene

GeneHancer (GH) Regulatory Elements Pubs

Promoters and enhancers for CYP4F2 Gene
GeneHancer (GH) Identifier GH Type GH
Score
GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites
Gene Targets
GH19J015898 Promoter 0.8 EPDnew 250.7 0.0 -17 0.1 NFIC YY1 HOMEZ RXRA FOSL2 DRAP1 TBP HNF4A RAD21 NFYC CYP4F2 HSALNG0124402-001 CYP4F11 lnc-OR7C2-1
GH19J015897 Enhancer 0.2 Ensembl 250.7 +0.9 876 0.4 CYP4F2 CLEC4OP lnc-CYP4F11-1 OR10H1 lnc-OR7C2-1
GH19J015892 Enhancer 0.5 Ensembl 14.6 +5.0 4976 1 RAD51 RXRA BHLHE40 HNF4A SP1 CLEC4OP CYP4F2 CYP4F11 lnc-CYP4F11-1 OR10H1 lnc-OR7C2-1
GH19J015499 Enhancer 0.8 FANTOM5 ENCODE 3.3 +398.8 398839 0.3 ZIC2 SP2 PKNOX1 GLIS1 REST SP1 CREB1 SP3 EGR2 PRDM10 PGLYRP2 CYP4F22 CYP4F2 CYP4F3 CYP4F11 OR10H4 OR1I1 RF00017-2584 lnc-OR7C2-1
GH19J015826 Promoter/Enhancer 2.6 EPDnew FANTOM5 Ensembl ENCODE CraniofacialAtlas dbSUPER 0.2 +65.3 65312 12.9 BCLAF1 SP1 NCOR1 MYC IKZF1 ZNF592 POLR2A NFIC ZBTB10 YY1 UCA1 ENSG00000273782 LINC01764 ENSG00000269578 SIN3B AKAP8 CYP4F24P OR10H4 AKAP8L MED26
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP4F2 on the GeneHancer Hub at the UCSC Golden Path

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP4F2

Top Transcription factor binding sites by QIAGEN in the CYP4F2 gene promoter:
  • FOXO4
  • GATA-2
  • HOXA5
  • HSF1 (long)
  • p53
  • Pax-2
  • Pax-2a
  • RORalpha1
  • STAT3
  • YY1

Genomic Locations for CYP4F2 Gene

Latest Assembly
chr19:15,878,023-15,898,077
(GRCh38/hg38)
Size:
20,055 bases
Orientation:
Minus strand

Previous Assembly
chr19:15,988,833-16,008,884
(GRCh37/hg19 by Entrez Gene)
Size:
20,052 bases
Orientation:
Minus strand

chr19:15,988,833-16,008,930
(GRCh37/hg19 by Ensembl)
Size:
20,098 bases
Orientation:
Minus strand

Genomic View for CYP4F2 Gene

Genes around CYP4F2 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP4F2 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP4F2 Gene
GeneLoc Logo Genomic Neighborhood Exon StructureGene Density

RefSeq DNA sequence for CYP4F2 Gene

Proteins for CYP4F2 Gene

  • Protein details for CYP4F2 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P78329-CP4F2_HUMAN
    Recommended name:
    Cytochrome P450 4F2
    Protein Accession:
    P78329
    Secondary Accessions:
    • A0A024R7K3
    • A8K425
    • B4DV75
    • Q16677
    • Q6NWT4
    • Q6NWT6
    • Q9NNZ0
    • Q9UIU8

    Protein attributes for CYP4F2 Gene

    Size:
    520 amino acids
    Molecular mass:
    59853 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    No Data Available

    Alternative splice isoforms for CYP4F2 Gene

    UniProtKB/Swiss-Prot:

neXtProt entry for CYP4F2 Gene

Post-translational modifications for CYP4F2 Gene

  • Modification sites at PhosphoSitePlus
  • Modification sites at neXtProt

Other Protein References for CYP4F2 Gene

No data available for DME Specific Peptides for CYP4F2 Gene

Domains & Families for CYP4F2 Gene

Gene Families for CYP4F2 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Disease related genes
  • Enzymes
  • Potential drug targets
  • Predicted intracellular proteins
  • Predicted membrane proteins

Protein Domains for CYP4F2 Gene

InterPro:
Blocks:
  • Group II E-class P450 signature

Suggested Antigen Peptide Sequences for CYP4F2 Gene

GenScript: Design optimal peptide antigens:
  • cDNA FLJ57164, highly similar to Cytochrome P450 4F2 (EC 1.14.13.30) (B4DV75_HUMAN)
  • Leukotriene-B(4) 20-monooxygenase 1 (CP4F2_HUMAN)
  • Cytochrome P450 (O95743_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P78329

UniProtKB/Swiss-Prot:

CP4F2_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP4F2: view

Function for CYP4F2 Gene

Molecular function for CYP4F2 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins (PubMed:18577768, PubMed:10833273, PubMed:10660572, PubMed:11997390, PubMed:17341693, PubMed:18574070). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs) (PubMed:18577768). Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:10660572, PubMed:17341693, PubMed:18574070). Plays a role in the oxidative inactivation of eicosanoids, including both proinflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs (PubMed:8026587, PubMed:9799565, PubMed:10833273, PubMed:10660572, PubMed:17341693, PubMed:18574070, PubMed:18577768). Catalyzes omega-hydroxylation of 3-hydroxy fatty acids (PubMed:18065749). Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites (PubMed:15145985). Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening (PubMed:16547005, PubMed:18182499). Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues (PubMed:11997390). Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation (PubMed:19297519, PubMed:24138531).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269|PubMed:10660572, ECO:0000269|PubMed:11997390, ECO:0000269|PubMed:24138531, ECO:0000269|PubMed:8026587};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39755, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76624; Evidence={ECO:0000269|PubMed:10660572, ECO:0000269|PubMed:17341693, ECO:0000269|PubMed:18577768, ECO:0000269|PubMed:24138531};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50164, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78043, ChEBI:CHEBI:132026; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39791, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76639; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40155, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77015, ChEBI:CHEBI:77016; EC=1.14.14.79; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53572, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84025, ChEBI:CHEBI:137474; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9S,10R)-epoxy-octadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-(9S,10R)-epoxy-octadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53552, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137458, ChEBI:CHEBI:137461; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9R,10S)-epoxy-octadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-(9R,10S)-epoxy-octadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53556, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137459, ChEBI:CHEBI:137460; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12,13-epoxy-(9Z)-octadecenoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-12,13-epoxy-(9Z)-octadecenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53568, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84026, ChEBI:CHEBI:137469; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=9,10-epoxy-(12Z)-octadecenoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-9,10-epoxy-(12Z)-octadecenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53564, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84023, ChEBI:CHEBI:137467; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=8-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 8,20-dihydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48660, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90716, ChEBI:CHEBI:90717; Evidence={ECO:0000269|PubMed:10833273};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 12,20-dihydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48664, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90718, ChEBI:CHEBI:90719; Evidence={ECO:0000269|PubMed:10833273};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12-hydroxyoctadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 12,18-dihydroxyoctadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49376, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84201, ChEBI:CHEBI:91294; Evidence={ECO:0000269|PubMed:10833273};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=docosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-hydroxydocosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40079, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:23858, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76304; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=22-hydroxydocosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-oxodocosanoate + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39055, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76298, ChEBI:CHEBI:76304; Evidence={ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=22-oxodocosanoate + O2 + reduced [NADPH--hemoprotein reductase] = docosanedioate + 2 H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39043, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76298, ChEBI:CHEBI:76299; Evidence={ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + tetracosanoate = 24-hydroxytetracosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39719, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:31014, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76610; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=hexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 26-hydroxyhexacosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40083, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:31013, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76305; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=26-hydroxyhexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 26-oxohexacosanoate + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39059, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76305, ChEBI:CHEBI:76311; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=26-oxohexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 2 H(+) + H2O + hexacosanedioate + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39047, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76311, ChEBI:CHEBI:76312; Evidence={ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=3-hydroxyoctadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 3,18-dihydroxyoctadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39735, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76614, ChEBI:CHEBI:76615; Evidence={ECO:0000269|PubMed:18065749};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=3-hydroxyhexadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 3,16-dihydroxyhexadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39731, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:63904, ChEBI:CHEBI:76613; Evidence={ECO:0000269|PubMed:18065749};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=leukotriene B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-leukotriene B4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:22176, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57460, ChEBI:CHEBI:57461, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.94; Evidence={ECO:0000269|PubMed:10833273, ECO:0000269|PubMed:8026587, ECO:0000269|PubMed:9799565};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=6-trans-leukotriene B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-6-trans-leukotriene B4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48676, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90723, ChEBI:CHEBI:90732; Evidence={ECO:0000269|PubMed:10833273};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=lipoxin A4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-lipoxin A4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48648, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:67026, ChEBI:CHEBI:90707; Evidence={ECO:0000269|PubMed:10833273};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=menaquinone-4 + O2 + reduced [NADPH--hemoprotein reductase] = H(+) + H2O + omega-hydroxymenaquinone-4 + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:41520, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78277, ChEBI:CHEBI:78278; EC=1.14.14.78; Evidence={ECO:0000269|PubMed:24138531};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + phylloquinone + reduced [NADPH--hemoprotein reductase] = H(+) + H2O + omega-hydroxyphylloquinone + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:41516, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:18067, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78276; EC=1.14.14.78; Evidence={ECO:0000269|PubMed:24138531};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(+)-alpha-tocopherol + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-alpha-tocopherol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:45108, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:18145, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84962; Evidence={ECO:0000269|PubMed:11997390};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=gamma-tocopherol + H(+) + NADPH + O2 = 13-hydroxy-gamma-tocopherol + H2O + NADP(+); Xref=Rhea:RHEA:45112, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:18185, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:84963; Evidence={ECO:0000269|PubMed:11997390};.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
Kinetic parameters: KM=0.5 uM for docosanoate {ECO:0000269|PubMed:16547005}; KM=1.1 uM for tetracosanoate {ECO:0000269|PubMed:16547005}; KM=1.9 uM for hexacosanoate {ECO:0000269|PubMed:16547005}; KM=75.2 uM for 12-hydroxyoctadecanoate {ECO:0000269|PubMed:10833273}; KM=19 uM for 8-HETE {ECO:0000269|PubMed:10833273}; KM=42.3 uM for 12-HETE {ECO:0000269|PubMed:10833273}; KM=37.6 uM for 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; KM=8.8 uM for 26-hydroxyhexacosanoate {ECO:0000269|PubMed:18182499}; KM=26.1 uM for 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; KM=163.1 uM for 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=135 uM for 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=60 uM for leukotriene B4 {ECO:0000269|PubMed:10833273}; KM=55.6 uM for 6-trans-leukotriene B4 {ECO:0000269|PubMed:10833273}; KM=58.2 uM for lipoxin A4 {ECO:0000269|PubMed:10833273}; KM=1.7 uM for menaquinone-4 (MK-4) {ECO:0000269|PubMed:24138531}; KM=21 uM for alpha-tocopherol {ECO:0000269|PubMed:11997390}; KM=37 uM for gamma-tocopherol {ECO:0000269|PubMed:11997390}; Vmax=1.6 pmol/min/pmol enzyme toward docosanoate {ECO:0000269|PubMed:16547005}; Vmax=1.6 pmol/min/pmol enzyme toward tetracosanoate {ECO:0000269|PubMed:16547005}; Vmax=0.9 pmol/min/pmol enzyme toward hexacosanoate {ECO:0000269|PubMed:16547005}; Vmax=7 nmol/min/nmol enzyme toward 12-hydroxyoctadecanoate {ECO:0000269|PubMed:10833273}; Vmax=4 nmol/min/nmol enzyme toward 8-HETE {ECO:0000269|PubMed:10833273}; Vmax=2.9 nmol/min/nmol enzyme toward 12-HETE {ECO:0000269|PubMed:10833273}; Vmax=1.6 pmol/min/pmol enzyme toward 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; Vmax=0.7 pmol/min/pmol enzyme toward 26-hydroxyhexacosanoate {ECO:0000269|PubMed:18182499}; Vmax=7.9 nmol/min/nmol enzyme toward 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; Vmax=10.6 nmol/min/nmol enzyme toward 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=0.84 nmol/min/nmol enzyme toward 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=2.7 nmol/min/nmol enzyme toward leukotriene B4 {ECO:0000269|PubMed:10833273}; Vmax=11.9 nmol/min/nmol enzyme toward 6-trans-leukotriene B4 {ECO:0000269|PubMed:10833273}; Vmax=5.5 nmol/min/nmol enzyme toward lipoxin A4 {ECO:0000269|PubMed:10833273}; Vmax=0.16 nmol/min/nmol enzyme toward alpha-tocopherol {ECO:0000269|PubMed:11997390}; Vmax=1.99 nmol/min/nmol enzyme toward gamma-tocopherol {ECO:0000269|PubMed:11997390}; Note=kcat is 0.067 min(-1) with menaquinone-4 (MK-4) as substrate (PubMed:24138531). The omega-hydroxylation of VLCFAs follows dual-enzyme Michaelis-Menten kinetics, suggesting simultaneous binding of two substrate molecules. The high affinity Michaelis-Menten constants are shown (PubMed:16547005). {ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:24138531};
UniProtKB/Swiss-Prot EnzymeRegulation:
Inhibited by dietary sesamin.
GENATLAS Biochemistry:
leukotriene B4 omega-hydroxylase,involved in the degradation of LTB4,a potent mediator of inflammation

Enzyme Numbers (IUBMB) for CYP4F2 Gene

Phenotypes From GWAS Catalog for CYP4F2 Gene

Gene Ontology (GO) - Molecular Function for CYP4F2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity IEA --
GO:0005506 iron ion binding IEA --
GO:0005515 protein binding IPI 17474147
GO:0008391 arachidonic acid monooxygenase activity IBA 21873635
GO:0008392 arachidonic acid epoxygenase activity IDA 9618440
genes like me logo Genes that share ontologies with CYP4F2: view
genes like me logo Genes that share phenotypes with CYP4F2: view

Animal Models for CYP4F2 Gene

MGI Knock Outs for CYP4F2:

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP4F2

No data available for Human Phenotype Ontology , miRNA , Transcription Factor Targets and HOMER Transcription for CYP4F2 Gene

Localization for CYP4F2 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP4F2 Gene

Microsome membrane. Peripheral membrane protein. Endoplasmic reticulum membrane. Peripheral membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP4F2 gene
Compartment Confidence
plasma membrane 5
extracellular 2
cytoskeleton 2
mitochondrion 2
peroxisome 2
nucleus 2
endoplasmic reticulum 2
cytosol 1
golgi apparatus 1
lysosome 0

Gene Ontology (GO) - Cellular Components for CYP4F2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005737 cytoplasm IDA 10660572
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS 20861217
GO:0016020 membrane IEA --
GO:0016021 integral component of membrane IEA --
genes like me logo Genes that share ontologies with CYP4F2: view

No data available for Subcellular locations from the Human Protein Atlas (HPA) for CYP4F2 Gene

Pathways & Interactions for CYP4F2 Gene

genes like me logo Genes that share pathways with CYP4F2: view

Pathways by source for CYP4F2 Gene

2 KEGG pathways for CYP4F2 Gene
1 GeneGo (Thomson Reuters) pathway for CYP4F2 Gene
  • HETE and HPETE biosynthesis and metabolism

UniProtKB/Swiss-Prot P78329-CP4F2_HUMAN

  • Pathway: Lipid metabolism; arachidonate metabolism.
  • Pathway: Lipid metabolism; leukotriene B4 degradation.
  • Pathway: Cofactor degradation; phylloquinone degradation.

Gene Ontology (GO) - Biological Process for CYP4F2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0000038 very long-chain fatty acid metabolic process IDA 18433732
GO:0001676 long-chain fatty acid metabolic process IDA 18433732
GO:0003091 renal water homeostasis IEP 10660572
GO:0003095 pressure natriuresis IEP 10660572
GO:0006629 lipid metabolic process IEA --
genes like me logo Genes that share ontologies with CYP4F2: view

No data available for SIGNOR curated interactions for CYP4F2 Gene

Drugs & Compounds for CYP4F2 Gene

(44) Drugs for CYP4F2 Gene - From: DrugBank, PharmGKB, ClinicalTrials, HMDB, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Vitamin K1 Approved, Investigational Pharma 347
Warfarin Approved Pharma 637
Acenocoumarol Approved, Investigational Pharma 46
Fingolimod Approved, Investigational Pharma Enzyme, substrate, inducer 0
Florbetaben (18F) Approved Pharma Enzyme, substrate 0

(7) Additional Compounds for CYP4F2 Gene - From: HMDB and Novoseek

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
20-Hydroxyeicosatetraenoic acid
  • (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoic acid
  • 20-Hydroxy arachidonic acid
  • 20-Hydroxyarachidonic acid
  • 20-Hydroxyicosatetraenoic acid
  • (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoate
79551-86-3
12(S)-Leukotriene B4
  • 12(S)-Leukotriene b4
  • 12-Epi-LTB4
  • 12S-LTB4
  • 5S,12S-Dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid
  • 5S,12S-Dihydroxy-6Z,8E,10E,14Z-eicosatetraenoate
83709-73-3
12-Keto-tetrahydro-leukotriene B4
  • 12-Keto-10,11,14,15-tetrahydro-LTB4
  • 5S-Hydroxy-12-keto-6Z,8E-eicosadienoate
  • 5S-Hydroxy-12-keto-6Z,8E-eicosadienoic acid
18-Hydroxyarachidonic acid
  • (18R)-HETE
  • (5Z,8Z,11Z,14Z,18R)-18-Hydroxyicosatetraenoic acid
  • 18(R)-Hydroxyeicosatetraenoic acid
  • Hydroxyarachidonic acid
  • (5Z,8Z,11Z,14Z,18R)-18-Hydroxyicosatetraenoate
124411-81-0
20-Hydroxy-leukotriene B4
  • (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoate
  • (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate
  • 20-Hydroxy-LTB4
  • 20-OH-Leukotriene b4
  • 20-OH-LTB4
79516-82-8
genes like me logo Genes that share compounds with CYP4F2: view

Transcripts for CYP4F2 Gene

mRNA/cDNA for CYP4F2 Gene

1 REFSEQ mRNAs :
11 NCBI additional mRNA sequence :
8 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP4F2

Alternative Splicing Database (ASD) splice patterns (SP) for CYP4F2 Gene

ExUns: 1a · 1b ^ 2 ^ 3 ^ 4 ^ 5a · 5b ^ 6 ^ 7 ^ 8 ^ 9a · 9b ^ 10 ^ 11
SP1:
SP2: -
SP3:
SP4:

Relevant External Links for CYP4F2 Gene

GeneLoc Exon Structure for
CYP4F2

Expression for CYP4F2 Gene

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP4F2 Gene

mRNA expression in embryonic tissues and stem cells from LifeMap Discovery

mRNA differential expression in normal tissues according to GTEx for CYP4F2 Gene

This gene is overexpressed in Liver (x40.4) and Small Intestine - Terminal Ileum (x4.8).

Protein differential expression in normal tissues from HIPED for CYP4F2 Gene

This gene is overexpressed in Gallbladder (35.0), Cervix (12.8), and Liver (12.1).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB, MaxQB, and MOPED for CYP4F2 Gene



Protein tissue co-expression partners for CYP4F2 Gene

- Elite partner

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP4F2

SOURCE GeneReport for Unigene cluster for CYP4F2 Gene:

Hs.558423

mRNA Expression by UniProt/SwissProt for CYP4F2 Gene:

P78329-CP4F2_HUMAN
Tissue specificity: Liver. Also present in kidney: specifically expressed in the S2 and S3 segments of proximal tubules in cortex and outer medulla (PubMed:10660572).

Evidence on tissue expression from TISSUES for CYP4F2 Gene

  • Liver(4.8)
  • Kidney(4.6)
  • Intestine(4.3)
  • Blood(2.3)
genes like me logo Genes that share expression patterns with CYP4F2: view

Primer products for research

No data available for Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP4F2 Gene

Orthologs for CYP4F2 Gene

This gene was present in the common ancestor of animals and fungi.

Orthologs for CYP4F2 Gene

Organism Taxonomy Gene Similarity Type Details
Chimpanzee
(Pan troglodytes)
Mammalia CYP4F2 30
  • 100 (a)
OneToOne
LOC748531 29
  • 94.36 (n)
Cow
(Bos Taurus)
Mammalia CYP4F2 29 30
  • 84.55 (n)
ManyToMany
-- 30
  • 83 (a)
ManyToMany
-- 30
  • 82 (a)
ManyToMany
-- 30
  • 81 (a)
ManyToMany
-- 30
  • 79 (a)
ManyToMany
Rat
(Rattus norvegicus)
Mammalia Cyp4f18 29
  • 78.78 (n)
Mouse
(Mus musculus)
Mammalia Cyp4f18 29 16
  • 78.59 (n)
Cyp4f13 30
  • 72 (a)
ManyToMany
Oppossum
(Monodelphis domestica)
Mammalia -- 30
  • 64 (a)
ManyToMany
-- 30
  • 64 (a)
ManyToMany
-- 30
  • 62 (a)
ManyToMany
-- 30
  • 62 (a)
ManyToMany
-- 30
  • 59 (a)
ManyToMany
Chicken
(Gallus gallus)
Aves -- 30
  • 72 (a)
OneToMany
Lizard
(Anolis carolinensis)
Reptilia -- 30
  • 64 (a)
ManyToMany
-- 30
  • 63 (a)
ManyToMany
Zebrafish
(Danio rerio)
Actinopterygii cyp4f3 29 30
  • 60.73 (n)
OneToMany
Fruit Fly
(Drosophila melanogaster)
Insecta Cyp4c3 31
  • 36 (a)
Cyp4d2 31
  • 36 (a)
Cyp4d8 31
  • 36 (a)
Cyp4g15 31
  • 36 (a)
Cyp4d1 31
  • 35 (a)
Cyp4d14 31
  • 35 (a)
Cyp4p1 31
  • 35 (a)
Cyp4s3 31
  • 35 (a)
Cyp4d20 31
  • 34 (a)
Cyp4ac3 31
  • 34 (a)
Cyp4ae1 31
  • 33 (a)
Cyp311a1 31
  • 32 (a)
Cyp312a1 31
  • 32 (a)
Cyp4ac1 31
  • 32 (a)
Cyp4d21 31
  • 32 (a)
Cyp4e1 31
  • 32 (a)
Cyp4e2 31
  • 32 (a)
Cyp4e3 31
  • 32 (a)
Cyp4p2 31
  • 32 (a)
Cyp4p3 31
  • 32 (a)
Cyp4ac2 31
  • 29 (a)
Cyp4ad1 31
  • 29 (a)
Cyp4aa1 31
  • 27 (a)
Cyp313a3 31
  • 27 (a)
Cyp313b1 31
  • 26 (a)
Cyp4g1 31
  • 26 (a)
Cyp313a4 31
  • 26 (a)
Cyp313a1 31
  • 25 (a)
Worm
(Caenorhabditis elegans)
Secernentea Y5H2B.5 31
  • 36 (a)
F01D5.9 31
  • 35 (a)
Y17G9B.3 31
  • 35 (a)
F28G4.1 31
  • 33 (a)
Y38C9B.1 31
  • 33 (a)
Y80D3A.5 31
  • 32 (a)
C26F1.2 31
  • 32 (a)
B0331.1 31
  • 31 (a)
Baker's yeast
(Saccharomyces cerevisiae)
Saccharomycetes DIT2 32
Sea Squirt
(Ciona savignyi)
Ascidiacea -- 30
  • 44 (a)
ManyToMany
-- 30
  • 43 (a)
ManyToMany
-- 30
  • 42 (a)
ManyToMany
CSA.8060 30
  • 41 (a)
ManyToMany
-- 30
  • 41 (a)
ManyToMany
CSA.3998 30
  • 40 (a)
ManyToMany
-- 30
  • 39 (a)
ManyToMany
-- 30
  • 39 (a)
ManyToMany
-- 30
  • 38 (a)
ManyToMany
CSA.6060 30
  • 38 (a)
ManyToMany
-- 30
  • 38 (a)
ManyToMany
-- 30
  • 38 (a)
ManyToMany
-- 30
  • 37 (a)
ManyToMany
-- 30
  • 32 (a)
ManyToMany
-- 30
  • 32 (a)
ManyToMany
Species where no ortholog for CYP4F2 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Eremothecium gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • African clawed frog (Xenopus laevis)
  • African malaria mosquito (Anopheles gambiae)
  • Alicante grape (Vitis vinifera)
  • Alpha proteobacteria (Wolbachia pipientis)
  • Amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • Barley (Hordeum vulgare)
  • Beta proteobacteria (Neisseria meningitidis)
  • Bread mold (Neurospora crassa)
  • Chromalveolata (Phytophthora infestans)
  • Common water flea (Daphnia pulex)
  • Corn (Zea mays)
  • Dog (Canis familiaris)
  • E. coli (Escherichia coli)
  • Filamentous fungi (Aspergillus nidulans)
  • Firmicute Bacteria (Streptococcus pneumoniae)
  • Fission Yeast (Schizosaccharomyces pombe)
  • Green Algae (Chlamydomonas reinhardtii)
  • Honey Bee (Apis mellifera)
  • K. Lactis Yeast (Kluyveromyces lactis)
  • Loblloly Pine (Pinus taeda)
  • Malaria Parasite (Plasmodium falciparum)
  • Medicago Trunc (Medicago Truncatula)
  • Moss (Physcomitrella patens)
  • Orangutan (Pongo pygmaeus)
  • Pig (Sus scrofa)
  • Platypus (Ornithorhynchus anatinus)
  • Rainbow Trout (Oncorhynchus mykiss)
  • Rice (Oryza sativa)
  • Rice Blast Fungus (Magnaporthe grisea)
  • Schistosome Parasite (Schistosoma mansoni)
  • Sea Anemone (Nematostella vectensis)
  • Sea Vase (Ciona intestinalis)
  • Sea Urchin (Strongylocentrotus purpuratus)
  • Sorghum (Sorghum bicolor)
  • Soybean (Glycine max)
  • Stem Rust Fungus (Puccinia graminis)
  • Sugarcane (Saccharum officinarum)
  • Thale Cress (Arabidopsis thaliana)
  • Tomato (Lycopersicon esculentum)
  • Toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • Tropical Clawed Frog (Silurana tropicalis)
  • Wheat (Triticum aestivum)

Evolution for CYP4F2 Gene

ENSEMBL:
Gene Tree for CYP4F2 (if available)
TreeFam:
Gene Tree for CYP4F2 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP4F2: view image
Alliance of Genome Resources:
Additional Orthologs for CYP4F2

Paralogs for CYP4F2 Gene

(14) SIMAP similar genes for CYP4F2 Gene using alignment to 6 proteins:

  • CP4F2_HUMAN
  • B4DV75_HUMAN
  • K7EK90_HUMAN
  • K7EPM0_HUMAN
  • K7EQI8_HUMAN
  • O95743_HUMAN

Pseudogenes.org Pseudogenes for CYP4F2 Gene

genes like me logo Genes that share paralogs with CYP4F2: view

Variants for CYP4F2 Gene

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP4F2 Gene

SNP ID Clinical significance and condition Chr 19 pos Variation AA Info Type
rs141338395 Benign: not provided 15,879,888(-) C/T
NM_001082.5(CYP4F2):c.1125G>A (p.Leu375=)
SYNONYMOUS
rs145174239 Benign: not provided 15,886,018(-) G/C
NM_001082.5(CYP4F2):c.1021C>G (p.Leu341Val)
MISSENSE
rs2108622 Drug Response: warfarin response - Other; acenocoumarol response - Dosage; phenprocoumon response - Dosage; warfarin response - Dosage 15,879,621(-) C/Tp.Val433Met
NM_001082.5(CYP4F2):c.1297G>A (p.Val433Met)
MISSENSE
rs3093136 Benign: not provided 15,892,578(-) G/C
NM_001082.5(CYP4F2):c.348C>G (p.Ala116=)
SYNONYMOUS
rs3093157 Likely Benign: not provided 15,889,510(-) A/G
NM_001082.5(CYP4F2):c.831T>C (p.Thr277=)
SYNONYMOUS

dbSNP identifiers (rs#s) for variants without ClinVar clinical significance for CYP4F2 Gene

All consequence types are included: molecular consequences (e.g. missense, synonymous), and location-based (e.g. intron, upstream).

Structural Variations from Database of Genomic Variants (DGV) for CYP4F2 Gene

Variant ID Type Subtype PubMed ID
dgv1721n106 CNV deletion 24896259
esv1124839 CNV deletion 17803354
esv1958771 CNV deletion 18987734
esv2671181 CNV deletion 23128226
esv2676393 CNV deletion 23128226
esv2718244 CNV deletion 23290073
esv2718247 CNV deletion 23290073
esv2718248 CNV deletion 23290073
esv2718249 CNV deletion 23290073
esv2718252 CNV deletion 23290073
esv3334671 CNV duplication 20981092
esv3643780 CNV loss 21293372
nsv1064684 CNV gain 25217958
nsv1072332 CNV deletion 25765185
nsv1077859 CNV duplication 25765185
nsv1110319 CNV duplication 24896259
nsv1133007 OTHER inversion 24896259
nsv1152249 CNV duplication 26484159
nsv833766 CNV loss 17160897
nsv960800 CNV duplication 23825009

Variation tolerance for CYP4F2 Gene

Residual Variation Intolerance Score: 97.4% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 11.59; 93.07% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP4F2 Gene

The Human Cytochrome P450 Allele Nomenclature Database
CYP4F2
Human Gene Mutation Database (HGMD)
CYP4F2
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP4F2
Leiden Open Variation Database (LOVD)
CYP4F2

SNP Genotyping and Copy Number Assays for research

No data available for Polymorphic Variants from UniProtKB/Swiss-Prot for CYP4F2 Gene

Disorders for CYP4F2 Gene

MalaCards: The human disease database

(7) MalaCards diseases for CYP4F2 Gene - From: COP and GCD

Disorder Aliases PubMed IDs
coumarin resistance
  • coumarin, poor metabolism of
atrial fibrillation
  • a-fib
thrombosis
  • thrombosis of blood vessel
inflammatory bowel disease 6
  • ibd6
ichthyosis
  • ichthyoses
- elite association - COSMIC cancer census association via MalaCards

UniProtKB/Swiss-Prot

CP4F2_HUMAN
  • Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti-coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269 PubMed:18250228, ECO:0000269 PubMed:19207028, ECO:0000269 PubMed:19270263, ECO:0000269 PubMed:19297519, ECO:0000269 PubMed:20555338, ECO:0000269 PubMed:23132553, ECO:0000269 PubMed:24138531}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry. The variant Met-433 is associated with coumarin (the brand name of warfarin) resistance by increasing coumarin maintenance dose in patients on this anti-coagulant therapy. This is probably due to decreased activity of the phylloquinone omega-hydroxylase activity, leading to an increase in hepatic vitamin K levels that warfarin must antagonize (PubMed:24138531). {ECO:0000269 PubMed:24138531}.

Additional Disease Information for CYP4F2

Human Genome Epidemiology Navigator
(HuGE)
Atlas
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
Open Targets Platform
Open Targets Platform
genes like me logo Genes that share disorders with CYP4F2: view

No data available for Genatlas for CYP4F2 Gene

Publications for CYP4F2 Gene

  1. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. (PMID: 19297519) McDonald MG … Rettie AE (Molecular pharmacology 2009) 3 4 22 40
  2. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. (PMID: 20227456) Deng S … Zhiyi H (Progress in neuro-psychopharmacology & biological psychiatry 2010) 3 22 40
  3. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. (PMID: 19270263) Pérez-Andreu V … González-Conejero R (Blood 2009) 3 4 40
  4. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. (PMID: 19207028) Borgiani P … Novelli G (Pharmacogenomics 2009) 3 4 40
  5. A genome-wide association study of acenocoumarol maintenance dosage. (PMID: 19578179) Teichert M … Stricker BH (Human molecular genetics 2009) 3 22 40

Products for CYP4F2 Gene

Sources for CYP4F2 Gene